More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$134106473
EPS
-0.27
P/E ratio
--
Price to sales
5.35
Dividend yield
--
Beta
-0.013472
Previous close
$3.17
Today's open
$2.96
Day's range
$2.80 - $3.12
52 week range
$1.95 - $6.40
show more
CEO
Ryan Rhodes
Employees
289
Headquarters
Vaulx-en-Velin,
Exchange
NASDAQ Global Market
Shares outstanding
47220589
Issue type
American Depository Receipt
Healthcare
Medical Distributors
EDAP TMS S.A. (FOCL) Presents at 2026 UBS Global Healthcare Conference Transcript
EDAP TMS S.A. ( FOCL ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Presentation Unknown Analyst Welcome, everybody.
Seeking Alpha • Nov 10, 2026

EDAP TMS S.A. (FOCL) Q3 2026 Earnings Call Transcript
EDAP TMS S.A. ( FOCL ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants Louisa Smith - Gilmartin Group LLC Alexander Nowak - Lucid Capital Markets, LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Presentation Operator Greetings, and welcome to the FocalTherics Third Quarter 2026 Conference Call.
Seeking Alpha • Nov 8, 2026

FocalTherics Q3 Earnings Call Highlights
FocalTherics NASDAQ: FOCL reported 26% growth in third-quarter 2026 revenue from its high-intensity focused ultrasound business, but lowered the top end of its full-year forecast after three anticipated system sales slipped into the fourth quarter.
MarketBeat • Nov 6, 2026

FocalTherics™ Reports Third Quarter 2026 Financial Results
FocalTherics™ Reports Third Quarter 2026 Financial Results 45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”1), a global leader in robotic focal therapy, today announced financial results for the third quarter of 2026. Third Quarter 2026 Results and Recent Highlights Increased Revenue to $9.8 million, a 26% Increase Compared to the Prior Year Period 32% Increase in U.S. Procedure Volume over the Prior Year Period Recorded Seven Focal One® Capital System Sales compared to Six in the Prior Year Period, Expanded Focal One System Installed Base to 192, including 98 in the U.S. and 94 Internationally Increased Gross Margin to 51.4%, Compared to 46.6% in the Prior Year Period Expanded Commercial Focal One Endometriosis Programs to Three Centers in Europe Positive Coverage Policies Published by Major Commercial Payers for HIFU in Radiorecurrent Prostate Cancer “We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France,” said Ryan Rhodes, CEO of FocalTherics.
GlobeNewsWire • Nov 5, 2026

FocalTherics™ to Participate in Upcoming Investor Conferences
FocalTherics ™ to Participate in Upcoming Investor Conferences
GlobeNewsWire • Nov 4, 2026

FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026
Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET
GlobeNewsWire • Oct 22, 2026

FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
FocalTherics ™ to Present at the H.C. Wain w right 28 th Annual Global Investment Conference Company to Present and Host 1x1 Investor Meetings on T uesday and Wednesday, September 15 th -16 th , 2026 AUSTIN, Texas, Sept.
GlobeNewsWire • Sep 1, 2026

FocalTherics Q2 Earnings Call Highlights
FocalTherics NASDAQ: FOCL reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy.
MarketBeat • Aug 14, 2026

EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 14, 2026

FocalTherics™ Reports Second Quarter 2026 Financial Results
FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.
GlobeNewsWire • Aug 13, 2026

¹ Disclosures

Open an M1 investment account to buy and sell EDAP TMS S.A. commission-free¹. Build wealth for the long term using automated trading and transfers.